Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
104.00    0.80 (0.78%)
Bid:
100.20
Ask:
105.80
Spread: 5.60 (5.589%)
Market Cap: £170.50m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading statement - Autumn 2025

23 Oct 2025 07:00

RNS Number : 4657E
Synthomer PLC
23 October 2025
 

Synthomer plcAutumn 2025 trading statement

Resilient performance in soft end-market environment

 

Synthomer plc ('Synthomer' or the 'Group') today issues a scheduled update on trading for the third quarter of 2025.

 

· Resilient Q3 2025 performance against a continuing soft market backdrop, led by Adhesive Solutions

· Additional self-help actions delivering an increasing benefit through the second half, mitigating subdued end-market conditions following trade tensions

· Expect Continuing EBITDA for 2025 to be similar to 2024

· Continued focus on strategic transformation and broadened divestment programme

 

Q3 2025 saw a continuation of soft demand across a number of end markets, which the Group was largely able to mitigate through our additional self-help initiatives. The Adhesive Solutions division continued to regain share and enhance margins, supported by our investment in increased APO capacity for adhesive applications at our Texas facility, which came onstream in July. Health & Protection volumes for the medical glove market remained subdued in the period, although our customers are increasingly confident of benefiting from their improved competitiveness in the US medical glove market following tariff changes. End markets in the Coatings & Construction Solutions division were more varied in the period - improving construction and relatively stable consumer sub-segments were offset by a slowdown in coatings demand particularly in the USA and low levels of oil and gas drilling activity affecting the energy solutions business. As anticipated, our 'in region, for region' manufacturing strategy means we are experiencing limited direct tariff impact which we are largely offsetting through surcharges, but we remain mindful that ongoing uncertainties around the global trade environment continue to create volatility in end-market demand.

 

As previously described, the Group has responded to the market environment by identifying additional rationalisation and cost efficiency opportunities. The new programme announced in August, which includes the removal of around 250 roles globally from the organisation, has now largely been completed and is on track to deliver c.£20-25m in savings on an annual run-rate basis by 2026. This programme supplements the previously identified benefits from robust pricing and the efficiency, reliability improvement and other 'self-help' actions implemented in 2025.

 

Alongside operational execution, we continue to focus on the strategic transformation of the Group and on strengthening our balance sheet. Having divested William Blythe in May, we continue to progress the Group's broadened divestment pipeline in order to accelerate the Group's deleveraging and simplify the portfolio further. Focus on cash generation is helping to ensure that the Group retains ample committed liquidity (after repayment of the stub 2025 bonds on 2 July 2025).

 

With our additional self-help actions largely mitigating the soft end-market demand conditions that we anticipate will persist for the remainder of 2025, we expect Continuing Group EBITDA for the year to be similar to the £143m reported in 2024, and expect a cash inflow in H2 to result in broadly neutral Free Cash Flow for the year. As we begin to look to 2026, we anticipate progress in Group earnings and cash generation as a result of full year contributions from our self-help actions and product investments.

 

Commenting, Synthomer CEO Michael Willome said:

"With ongoing global geopolitical and tariff-related turbulence continuing to unbalance demand and supply in our end markets, we have sharpened our focus on what we can control - expanding our cost saving programme, accelerating the transformation of our business portfolio and allocating resources even more rigorously to strengthen our financial position. We have clear commercial, operational and strategic plans in place, which are contributing to greater resilience and a stronger portfolio mix with considerable operating leverage to end-market demand recovery. As such, we remain confident in our objective to double Synthomer's recent earnings levels in the medium term, through our cost actions and strategy of focusing the business on market-leading speciality products with sustainable, differentiated benefits for global end-users."

 

Further information:

Investors: Faisal Tabbah, Vice President Investor Relations

Tel: +44 (0) 1279 775 306

Media: Nick Hasell, FTI Consulting

Tel: +44 (0) 203 727 1340

 

Notes

Synthomer plc is a leading supplier of high-performance, highly specialised polymers and ingredients that play vital roles in key sectors such as coatings, construction, adhesives, and health and protection - growing markets for customers who serve billions of end users worldwide. Headquartered in London, UK and listed there since 1971, we employ c.3,900 employees across our five innovation centres of excellence and 29 manufacturing sites across Europe, North America, Middle East and Asia. With more than 6,000 blue-chip customers and £2.0bn in continuing revenue in 2024, our business is built around three divisions, serving customers in attractive end markets where demand is driven by global megatrends including urbanisation, demographic change, climate change and sustainability, and shifting economic power.

 

In Coatings & Construction Solutions, our specialist polymers enhance the sustainability and performance of a wide range of coatings and construction products. We serve customers in applications including architectural and masonry coatings, mortar modification, waterproofing and flooring, fibre bonding, and energy solutions. In Adhesive Solutions our products help our customers bond, modify and compatibilise surfaces and components for applications including tapes and labels, packaging, hygiene, tyres and plastic modification, improving permeability, strength, elasticity, damping, dispersion and grip. In Health & Protection and Performance Materials we are a world-leading supplier of water-based polymers for medical gloves, and a major European manufacturer of high-performance binders, foams and other products serving customers in a range of end markets.

 

Our purpose is creating innovative and sustainable solutions for the benefit of customers and society. Around 20% of our sales volumes are from new and patent protected products. At our innovation centres of excellence in the UK, China, Germany, Malaysia and Ohio, USA we collaborate closely with our customers to develop new products and enhance existing ones tailored to their needs, with an increasing range of sustainability benefits. Our 2030 decarbonisation targets have been approved by the Science Based Targets initiative as being in line with what the latest climate science says is necessary to meet the goals of the Paris Agreement, and since 2021 we have held the London Stock Exchange Green Economy Mark, which recognises green technology businesses making a significant contribution to a more sustainable, low-carbon economy. Find us at www.synthomer.com or search for Synthomer on LinkedIn.

 

Legal Entity Identifier (LEI): 213800EHT3TI1KPQQJ56. Classification as per DTR 6 Annex 1R: 3.1.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFFDIVLFFIE
Date   Source Headline
4th Sep 20203:15 pmRNSDirector Declaration
6th Aug 20207:00 amRNSInterim Results for six months ended 30 June 2020
27th Jul 202010:00 amRNSPost Stabilisation Notice
16th Jul 20207:00 amRNSAppointment of Non-Executive Director
8th Jul 20204:16 pmRNSHolding(s) in Company
8th Jul 20204:14 pmRNSHolding(s) in Company
19th Jun 20207:00 amRNSSynthomer announces the pricing of senior notes
16th Jun 202011:54 amRNSPre Stabilisation Notice
16th Jun 202010:11 amRNSQ2 trading update
11th May 20205:21 pmRNSHolding(s) in Company
11th May 20209:03 amRNSDirector/PDMR Shareholding
11th May 20209:02 amRNSDirector/PDMR Shareholding
11th May 20208:59 amRNSDirector/PDMR Shareholding
11th May 20208:58 amRNSDirector/PDMR Shareholding
29th Apr 20203:17 pmRNSResult of AGM
29th Apr 20207:00 amRNSQ1 Trading and COVID-19 Update
1st Apr 20202:44 pmRNSCompletion of OMNOVA acquisition
1st Apr 20207:00 amRNSAnnual Financial Report
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSAppointment of Deputy Chair and Chair-elect
26th Mar 202010:17 amRNSEuropean Commission clearance for OMNOVA
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
16th Mar 20209:50 amRNSDirector/PDMR Shareholding
13th Mar 20205:29 pmRNSDirector/PDMR Shareholding
9th Mar 20202:45 pmRNSHolding(s) in Company
5th Mar 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
31st Jan 20209:36 amRNSDirector Declaration
15th Jan 20202:21 pmRNSAcquisition of OMNOVA receives EC clearance
6th Dec 20197:00 amRNSAppointment of Broker
13th Nov 20192:53 pmRNSDirector/PDMR Shareholding
11th Nov 20197:00 amRNSDirector Declaration
25th Oct 20197:00 amRNSQ3 Trading Update
22nd Oct 20197:00 amRNSAGM Statement
11th Oct 20197:00 amRNSOmnova shareholders approval
14th Aug 20193:25 pmRNSHolding(s) in Company
13th Aug 201912:33 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
2nd Aug 201910:29 amRNSHolding(s) in Company
1st Aug 20199:05 amRNSHolding(s) in Company
31st Jul 201910:51 amRNSResults of Extraordinary General Meeting
30th Jul 20191:07 pmRNSDirector/PDMR Shareholding
30th Jul 20191:03 pmRNSDirector/PDMR Shareholding
30th Jul 20191:02 pmRNSDirector/PDMR Shareholding
30th Jul 20191:01 pmRNSDirector/PDMR Shareholding
30th Jul 201912:59 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:55 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.